Teva to invest USD 42 mln in new drug plant in Bulgaria
Israel-based Teva Pharmaceutical Industries will make a strategic investment of some USD 42 million (EUR 35 million) in the construction of a new drug production plant in the Bulgarian town of Dupnitsa, it said.
The new plant will complement Teva's existing manufacturing facility in Dupnitsa, in southwestern Bulgaria, significantly increasing production capacity by over 800 million tablets/capsules per year and creating about 70 new jobs, the company said in a statement.
Production at the new plant is expected to begin at the end of 2023 after the facility receives approval from the respective regulatory bodies.
MOL Shareholders Approve Dividend of Around HUF 250/Share
Gov't Awards HUF 6.5 bln of Subsidies to SMEs in Underdevelo...
Hungary's Largest ESG Consultancy Formed by Merger of EY, De...
Liz & Chain Rooftop Bar Debuts Sustainable Cocktails
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
